Abstract
Sunitinib is an oral antityrosine kinase inhibitor that has antiangiogenic and antitumor activities. It has been approved for the treatment of advanced RCC and for imatinib-refractory gastrointestinal stromal tumors (GIST). Tumor lysis syndrom can occur in solid tumors. We report a case of patient with metastatic RCC treated with sunitinib with a diagnosis of tumor lysis syndrome.
MeSH terms
-
Angiogenesis Inhibitors / adverse effects*
-
Angiogenesis Inhibitors / therapeutic use*
-
Humans
-
Indoles / adverse effects*
-
Indoles / therapeutic use*
-
Kidney Neoplasms / complications
-
Kidney Neoplasms / diagnostic imaging
-
Kidney Neoplasms / drug therapy*
-
Male
-
Middle Aged
-
Pyrroles / adverse effects*
-
Pyrroles / therapeutic use*
-
Sunitinib
-
Tomography, X-Ray Computed
-
Tumor Lysis Syndrome / diagnostic imaging
-
Tumor Lysis Syndrome / etiology*
-
Ultrasonography
Substances
-
Angiogenesis Inhibitors
-
Indoles
-
Pyrroles
-
Sunitinib